Reduced testosterone, 17β-oestradiol and sexual hormone binding globulin, and increased insulin-like growth factor-1 concentrations, in healthy nulligravid women aged 19-25 years who were first and/or second degree relatives to breast cancer patients

European Journal of Cancer Prevention

Volumn 6, Issue 4, 1997, Pages 330-340

  Jernstrom H C B ^a   Olsson, H ^a   Borg, A ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

17 oestradiol; Breast cancer; Familial breast cancer; IGF 1; Nulligravida; SHBG; Testosterone

Indexed keywords

ESTRADIOL; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TESTOSTERONE;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; ESTRADIOL BLOOD LEVEL; FAMILY HISTORY; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN EXPERIMENT; MENSTRUAL CYCLE; NORMAL HUMAN; NULLIPARA; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; TESTOSTERONE BLOOD LEVEL;

ADULT; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL; ESTRADIOL; FAMILY; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; PEDIGREE; REFERENCE VALUES; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 0030831032     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-199708000-00004     Document Type: Article

References (41)

1. Anderson T, Battersby S, King R, McPherson K, Going J (1989). Oral contraceptive use influences resting breast proliferation. Human Pathol 20: 1139-44.
2. Apter D, Reinilä M, Vihko R (1989). Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. Int J Cancer 44: 783-7.
3. Bernstein L, Ross R (1993). Endogenous hormones and breast cancer risk. Epidemiol Rev 15: 48-65.
4. Boffard K, Clark G, Irvine J et al (1981). Serum prolactin, androgens, oestradiol and progesterone in adolescent girls with and without a family history of breast cancer. Eur J Cancer 17: 1071-7.
5. Braund W, Roger D, Judd S (1984). Synchronous secretion of lutenizing hormone and prolactin in the human luteal phase: neuroendocrine mechanisms. J Clin Endocrinol Metab 58: 293-7.
6. Brisson J, Morrison A, Kopans D et al (1984). Height and weight, mammographic features of breast tissue, and breast cancer risk. Am J Epidemiol 119: 371-81.
7. Bruning P, Bonfrèr J, Hart A et al (1992). Body measurements, estrogen availability and the risk of human breast cancer: a case-control study. Int J Cancer 51(1): 14-9.
8. Bruning P, Van Doorn J, Bonfrèr J et al (1995). Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 62(3): 266-70.
9. Bulbrook R, Thomas B (1989). Hormones are ambiguous risk factors for breast cancer. Acta Oncol 28: 841-7.
10. Claus E, Rish N, Thompson W (1991). Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48: 232-42.
11. Collaborative Group on Hormonal Factors in Breast Cancer (1996). Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713-27.
12. Dunn J, Nisula B, Rodbard D (1981). Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 53: 58-68.
13. Henderson B, Gerkins V, Rosario I, Casagrande J, Pike M (1975). Elevated serum levels of estrogen and prolactin in daughters of patients with breast cancer. N Engl J Med 293: 790-5.
14. Jones J, Clemmons D (1995). Insulin-like growth factors and their binding proteins: biological actions. Endocrinol Rev 16: 3-34.
15. Kazer R (1995). Insulin resistance, insulin-like growth factor 1 and breast cancer: a hypothesis. Int J Cancer 62: 403-6.
16. Kelsey J, Gammon M, John E (1993). Reproductive factors and breast cancer. Epidemiol Rev 15: 36-47.
17. Key T, Pike M (1988). The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 24: 29-43.
18. Kirschner M, Samojlik E, Drejka M, Szmal E, Schneider G, Ertel N (1990). Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab 70: 473-9.
19. London S, Colditz G, Stampfer M et al (1989). Prospective study of relative weight height, and risk of breast cancer. JAMA 262: 2853-8.
20. Love R, Rose D (1985). Elevated bioactive prolactin in women at risk for familial breast cancer. Eur J Cancer Clin Oncol 22: 1553-4.
21. MacMahon B, Cole P, Lin P et al (1970). Age at first birth and breast cancer risk. Bull WHO 43(2): 209-21.
22. Malkin D, Li P, Strong L et al (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250: 1233-8.
23. Marquis S, Rajan J, Wynshaw-Boris A et al (1995). The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 11: 17-26.
24. Masaoka K, Kitazawa M, Kumasaka T (1988). Pulsatile secretion of prolactin and luteinizing hormone and their synchronous relationship during the human menstrual cycle. Gynecol Endocrinol 2: 293-303.
25. Miki Y, Swensen J, Shattuck-Eidens D et al (1994). A strong candidate for breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71.
26. Moore J, Key T, Bulbrook R et al (1987). Sex hormone binding globulin and risk factors for breast cancer in a population of normal women who had never used exogenous sex hormones. Br J Cancer 56: 661-6.
27. Nilsson B, von Schoultz B (1989). Binding of levonorgestrel, norethisterone and desogestrel to human sex hormone binding globulin and influence on free testosterone levels. Gynecol Obstet Invest 27: 151-4.
28. Olsson H (1990). Reproductive and hormonal factors in relation to cancer occurrence in the breast, prostate, testis, uterine corpus, ovary, uterine cervix, and thyroid gland. In Cancer and Aging (eds Macieira-Coelho A, Nordenskjöld B); CRC Press, Ann Arbor Boston, pp. 109-26.
29. Olsson H, Möller T, Ranstam J (1989). Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden. J Natl Cancer Inst 81: 1000-4.
30. Reubinoff B, Grubstein A, Meirow D, Berry E, Shenker J, Brzezinski A (1995). Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women. Fertil Steril 63: 516-21.
31. Russo J, Russo IH (1994). Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prev 3: 353-64.
32. Secreto G, Fariselli G, Bandieramonte G, Recchione C, Dati V, Di Pietro S (1983). Androgen excretion in women with a family history of breast cancer or with epithelial hyperplasia or cancer of the breast. Eur J Cancer Clin Oncol 19(1): 5-10.
33. Secreto G, Recchione C, Fariselli G, Di Pietro S (1984). High testosterone and low progesterone circulating levels in premenopausal patients with hyperplasia and cancer of the breast. Cancer Res 44: 841-4.
34. Smith S, Easton D, Evans D, Ponder B (1992). Allele losses in the region 17q 12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 2: 128-31.
35. Thomas D (1984). Do hormones cause cancer? Cancer 53(Suppl): 595-604.
36. Thompson M, Jensen R, Obermiller P, Page D, Holt J (1995). Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9(4): 444-50.
37. Trichipoulos D, Brown J, Garas J, Papaioannou A, MacMahon B (1981). Elevated urine estrogen and pregnanediol levels in daughters of breast cancer patients. J Natl Cancer Inst 67: 603-6.
38. van der Vange N, Blankenstein M, Kloosterboer H, Haspels A, Thijssen J (1990). Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 41: 345-52.
39. Wolf D, Wiltschke C, Castles C, Allred D, O Connell P, Fuqua S (1995). The role of ER mutations in breast carcinogenesis and progression. Abstract from International Symposium on the Molecular Biology of Breast Cancer. Lillehammer Norway, March 1-5, S3.
40. Wooster R, Neuhausen S, Mangion J et al (1994). Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265: 2088-90.
41. Wysowski D, Comstock G, Helsing K, Lau H (1987). Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 125: 791-9.